Physician profile
John C Lee
NPI 1740240803
$5,426.08
in general payments reported to CMS, 2019-2025
35 companies · $600 in 2025
The $600 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $218 · 2021: $563 · 2022: $1,249 · 2023: $2,046 · 2024: $32.71 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,678.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,593.09 | 2019-2025 | |
| Celgene Corporation | $768.91 | 2022-2023 | Zeposia |
| Boston Scientific Corporation | $671.97 | 2022-2023 | Rotablator Rotational Atherectomy System Console Kit, Avvigo Guidance System, Synergy |
| Janssen Biotech, INC. | $386.40 | 2019-2023 | Stelara |
| Phathom Pharmaceuticals, INC. | $239.27 | 2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $227.48 | 2022-2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $185.49 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.35 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $134.13 | 2022-2023 | Dificid |
| Aimmune Therapeutics, INC. | $124.98 | 2025 | Zenpep |
| Shionogi INC | $96.97 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $88.94 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $78.14 | 2022-2023 | Dupixent |
| Genzyme Corporation | $71.66 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $66.02 | 2019-2023 | Clenpiq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $64.65 | 2025 | Ibsrela |
| Micro-Tech Endoscopy USA, INC. | $50.38 | 2019 | |
| Madrigal Pharmaceuticals | $46.90 | 2025 | Rezdiffra |
| Redhill Biopharma INC. | $42.28 | 2022 | |
| Ironwood Pharmaceuticals, INC | $38.75 | 2019-2023 | Linzess |
| Qol Medical, LLC | $34.74 | 2020-2021 | |
| Braintree Laboratories, INC. | $26.18 | 2023 | Sutab |
| Pfizer INC. | $24.46 | 2025 | |
| Shire North American Group INC | $23.05 | 2019 | |
| Intra-Sana Laboratories | $19.96 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Ethicon US, LLC | $19.14 | 2019 | |
| Amgen INC. | $17.31 | 2025 | Uplizna |
| Daiichi Sankyo INC. | $15.93 | 2019 | |
| Edwards Lifesciences Corporation | $15.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.59 | 2019 | |
| Olympus America INC. | $15.44 | 2021 | |
| Fresenius Kabi USA, LLC | $13.36 | 2023 | Idacio |
| Medtronic Vascular, INC. | $12.76 | 2019 | |
| Medtronic, INC. | $12.74 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$15,422.75 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.